Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKWELL MEDICAL, INC.RMTI · Entity 7426 | Director | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKWELL MEDICAL, INC.
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,985 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 9,633 · Balance 23,985 F1: Restricted stock units vest on July 1, 2027, subject to the Reporting Person's continued service to the Issuer through the 2027 Annual Meeting. F2: Effective at 12:01 AM on July 1, 2026, the Issuer effected a 1-for-10 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, the shares listed under Amount of Securities Beneficially Owned Following Reported Transaction(s) reported in this Form 4 have been adjusted to reflect the 1-for-10 reverse split. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units vest on July 1, 2027, subject to the Reporting Person's continued service to the Issuer through the 2027 Annual Meeting.
F2: Effective at 12:01 AM on July 1, 2026, the Issuer effected a 1-for-10 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, the shares listed under Amount of Securities Beneficially Owned Following Reported Transaction(s) reported in this Form 4 have been adjusted to reflect the 1-for-10 reverse split.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Paratek Pharmaceuticals, Inc.
Report date September 21, 2023 · Filed September 21, 2023
Section 16 reporting ended · disclosed 2023-09-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2023-09-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-21 · Disposition to issuer · Disposed 53,000 · Balance 20,000 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, F2: (Continued from Footnote 1) without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. F3: Due to administrative error, the Reporting Person's previous Form 4 filings under-reported the securities beneficially owned by the Reporting Person by 750 shares of common stock of the Issuer. This filing corrects such error and lists the correct amount of securities beneficially owned directly by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F5: (Continued from Footnote 4) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2031-02-18 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2030-02-19 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.23 · Expires 2029-02-26 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.15 · Expires 2028-02-14 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.10 · Expires 2027-02-01 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-09-21 · Disposition to issuer · Disposed 6,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.05 · Expires 2026-02-03 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-09-21 · Disposition to issuer · Disposed 12,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.07 · Expires 2029-02-26 | Direct | 0 |
Reported balance
After 2023-09-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash,
F2: (Continued from Footnote 1) without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC.
F3: Due to administrative error, the Reporting Person's previous Form 4 filings under-reported the securities beneficially owned by the Reporting Person by 750 shares of common stock of the Issuer. This filing corrects such error and lists the correct amount of securities beneficially owned directly by the Reporting Person.
F4: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration,
F5: (Continued from Footnote 4) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger.
F6: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Zyla Life Sciences
Report date December 31, 2019 · Filed January 02, 2020
Section 16 reporting ended · disclosed 2020-01-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,915 |
Ending reported balance
After 2019-12-31 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-12-31 · Exercise / conversion · Acquired 66,000 · Balance 66,000 F1: Accelerated vesting of time-based restricted stock units pursuant to the reporting person's Separation and General Release Agreement. Such restricted stock units were scheduled to vest on March 26, 2020. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately. Row 2 · 2019-12-31 · Exercise / conversion · Acquired 66,000 · Balance 132,000 F2: Accelerated vesting of performance-based restricted stock units pursuant to the reporting person's Separation and General Release Agreement. Such restricted stock units were eligible to vest on March 26, 2020. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately. Row 3 · 2019-12-31 · Tax withholding · Disposed 55,085 · Balance 76,915 F3: Represents shares withheld to pay taxes applicable to vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-12-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-31 · Exercise / conversion · Acquired 66,000 · Balance 0 F4: Restricted Stock Units convert into Common Stock on a one-for-one basis. F5: On March 26, 2019, the reporting person was granted 66,000 restricted stock units that were scheduled to vest on March 26, 2020. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-12-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-31 · Exercise / conversion · Acquired 66,000 · Balance 0 F4: Restricted Stock Units convert into Common Stock on a one-for-one basis. F6: On March 26, 2019 the reporting person was granted 66,000 performance-based restricted stock units that were eligible to vest on March 26, 2020, subject to the Company's achievement of at least 75% of its 2019 Corporate Goals, as set by the Board in March 2019, with the exact number of performance-based RSUs vesting pro-rated based on the level of achievement between 75% and 100%. |
Filing footnotes · ownership attribution and instrument terms
F1: Accelerated vesting of time-based restricted stock units pursuant to the reporting person's Separation and General Release Agreement. Such restricted stock units were scheduled to vest on March 26, 2020. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately.
F2: Accelerated vesting of performance-based restricted stock units pursuant to the reporting person's Separation and General Release Agreement. Such restricted stock units were eligible to vest on March 26, 2020. The restricted stock units represent the right to receive an equal number of shares of Common Stock issued pursuant to the Zyla Life Sciences 2019 Stock-Based Incentive Compensation Plan. The shares are convertible into Common Stock immediately.
F3: Represents shares withheld to pay taxes applicable to vesting of restricted stock units.
F4: Restricted Stock Units convert into Common Stock on a one-for-one basis.
F5: On March 26, 2019, the reporting person was granted 66,000 restricted stock units that were scheduled to vest on March 26, 2020.
F6: On March 26, 2019 the reporting person was granted 66,000 performance-based restricted stock units that were eligible to vest on March 26, 2020, subject to the Company's achievement of at least 75% of its 2019 Corporate Goals, as set by the Board in March 2019, with the exact number of performance-based RSUs vesting pro-rated based on the level of achievement between 75% and 100%.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2017 Filed Feb 6, 2017 19:21 UTC | Paratek Pharmaceuticals, Inc. PRTK · Entity 109529 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-17-000105 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: The shares shall vest on the one-year anniversary of February 2, 2017, subject to the Reporting Person's continued service to the Company at the vesting date. Read SEC document |
| December 12, 2016 Filed Dec 13, 2016 17:13 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0001179110-16-032878 · edgar.xml · derivative · entry 1 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-12-12 F1 · derivative.exercise_date: The option vests with respect to one-fourth of the underlying shares on the first anniversary of the grant date and with respect to one-forty eighth of the underlying shares each month thereafter until fully vested. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 16:25 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001179110-16-032587 · edgar.xml · derivative · entry 1 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-12-06 F1 · derivative.exercise_date: The option vests with respect to one-fourth of the underlying shares on the first anniversary of the grant date and with respect to one-forty eighth of the underlying shares each month thereafter until fully vested. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 16:23 UTC | Zyla Life Sciences EGLT · Entity 148990 | SaleCommon Stock | 15,000 | $7.47 | $112,050.00 |
DisclosureSEC source: 0001179110-16-030279 · edgar.xml · nonDerivative · entry 1 Radie Robert S · CIK 0001591113 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,900 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on February 11, 2014. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.37 to $7.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.